Oneprojects has established itself as German-Irish medtech startup specializes in innovations in cardiac imaging. The €11 million Series A financing round was led by Life Sciences Partners of the Netherlands. Additional capital came from the Atlantic Bridge University Fund, Enterprise Ireland, and a select group of international medical technology entrepreneurs.
4D images for the treatment of cardiac arrhythmias
Founded in 2017 by Fionn Lahart (CEO) and Christoph Hennersperger (CTO) in Dublin, essential Development work of the startup in Munich Under the name Verafeye, the company develops an innovative technology in the field of medical imaging. The founders founded Oneprojects from a research project at Ireland's Trinity College Dublin. Among other things, the company focuses Medtech to better treat cardiac arrhythmias such as atrial fibrillation – a disease that affects over 38 million people worldwide.
Atrial fibrillation is a serious cardiac arrhythmia caused by chaotic electrical signals in the heart. The condition is one of the most common causes of stroke and heart disease. Atrial fibrillation is typically treated with catheter ablation, but this is only successful in about half of all procedures performed. Therefore, many patients require repeat treatment. Using innovative imaging and data analysis combined with a catheter-based sensor system, Verafeye displays high-quality 4D image data of the heart. This is intended to make catheter ablations more effective and safer.
Financing is intended to give Oneprojects a boost towards commercialization
The funding will be used for further product development, clinical trials, and preparations for commercialization of the system in the United States.
Fionn Lahart, CEO and co-founder of the medtech, comments:
“This investment will help us further expand our team in Dublin and Munich, advance product development, and ultimately achieve our goal of offering a far better treatment for patients with atrial fibrillation.”
The founder builds on the experience of the investors in the healthcare sector, who become part of the board.
Potential for better and more cost-effective treatment
Drew Burdon, Investment Manager at LSP, says:
“Verafeye has the potential to positively impact the current clinical situation by providing better treatment for the many patients who suffer needlessly today, while also providing significant savings for the healthcare system.”
